Trevi Therapeutics Expands Leadership with David Hastings as CFO to Drive Growth
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company based in New Haven, announced a significant change in its executive leadership as David Hastings is set to join the firm as Chief Financial Officer (CFO) starting January 6, 2026. This move comes at a crucial time for the company, which is developing Haduvio™, an investigational therapy for chronic cough conditions. With over 25 years of financial experience in public life sciences and biotech, Hastings is expected to play a pivotal role in guiding Trevi through its next growth phase.
Hastings’s career has been marked by numerous accomplishments, particularly in capital raising, commercialization strategies, and managing investor relations, which hold great importance as Trevi gears up for Phase 3 development of Haduvio. His impressive track record includes raising more than $2 billion in equity and debt financing, underscoring his capacity to secure necessary funding for R&D initiatives and operational growth.
Previously, Hastings served as CFO at Arbutus Biopharma from June 2018 until March 2025, followed by a tenure at Unilife from 2015 to 2017, where he was instrumental in financial operations. His time spent at Incyte as CFO and Executive Vice President further solidified his reputation, where he oversaw the company's transition towards commercialization, specifically focusing on Jakafi® (ruxolitinib). His leadership helped expand the company’s workforce significantly, reflecting his adeptness at steering financial complexities during expansion phases.
Jennifer Good, President and CEO of Trevi Therapeutics, expressed her enthusiasm for Hastings joining the team, highlighting the importance of his experience as the company makes advances in its development journey. Hastings himself expressed optimism about joining a company at the forefront of addressing chronic cough, emphasizing the significant clinical data supporting Haduvio’s development and its potential to create long-term value.
Haduvio™ (oral nalbuphine ER) is in the pipeline for treating chronic cough associated with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). This therapy is distinguished as the first investigational treatment to demonstrate statistically significant reductions in cough frequency through its unique mechanism of action involving opioid receptor modulation.
The market environment for Trevi is compelling, with approximately 150,000 patients suffering from IPF in the U.S. alone, many of whom experience uncontrollable coughing. Non-IPF ILD patients also face similar challenges, with significant percentages experiencing chronic cough. Hastings's leadership is perceived as critical for navigating the upcoming challenges and opportunities in advancing Haduvio through clinical trials.
As Trevi Therapeutics forges ahead under Hastings's financial guidance, the company remains focused on providing effective therapies for chronic cough, a previously unmet medical need that affects millions of patients. With the impending launch of Haduvio and Hastings's strategic oversight, Trevi is poised to make meaningful advances in its mission to improve patient outcomes and shareholder value.
For further inquiries, interested parties can visit Trevi Therapeutics' official website or follow its activities on social media platforms like X (formerly Twitter) and LinkedIn. As the company approaches pivotal milestones, updates regarding Haduvio and company performance are expected to shape public interest in Trevi’s operations moving forward.
Hastings’s career has been marked by numerous accomplishments, particularly in capital raising, commercialization strategies, and managing investor relations, which hold great importance as Trevi gears up for Phase 3 development of Haduvio. His impressive track record includes raising more than $2 billion in equity and debt financing, underscoring his capacity to secure necessary funding for R&D initiatives and operational growth.
Previously, Hastings served as CFO at Arbutus Biopharma from June 2018 until March 2025, followed by a tenure at Unilife from 2015 to 2017, where he was instrumental in financial operations. His time spent at Incyte as CFO and Executive Vice President further solidified his reputation, where he oversaw the company's transition towards commercialization, specifically focusing on Jakafi® (ruxolitinib). His leadership helped expand the company’s workforce significantly, reflecting his adeptness at steering financial complexities during expansion phases.
Jennifer Good, President and CEO of Trevi Therapeutics, expressed her enthusiasm for Hastings joining the team, highlighting the importance of his experience as the company makes advances in its development journey. Hastings himself expressed optimism about joining a company at the forefront of addressing chronic cough, emphasizing the significant clinical data supporting Haduvio’s development and its potential to create long-term value.
Haduvio™ (oral nalbuphine ER) is in the pipeline for treating chronic cough associated with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). This therapy is distinguished as the first investigational treatment to demonstrate statistically significant reductions in cough frequency through its unique mechanism of action involving opioid receptor modulation.
The market environment for Trevi is compelling, with approximately 150,000 patients suffering from IPF in the U.S. alone, many of whom experience uncontrollable coughing. Non-IPF ILD patients also face similar challenges, with significant percentages experiencing chronic cough. Hastings's leadership is perceived as critical for navigating the upcoming challenges and opportunities in advancing Haduvio through clinical trials.
As Trevi Therapeutics forges ahead under Hastings's financial guidance, the company remains focused on providing effective therapies for chronic cough, a previously unmet medical need that affects millions of patients. With the impending launch of Haduvio and Hastings's strategic oversight, Trevi is poised to make meaningful advances in its mission to improve patient outcomes and shareholder value.
For further inquiries, interested parties can visit Trevi Therapeutics' official website or follow its activities on social media platforms like X (formerly Twitter) and LinkedIn. As the company approaches pivotal milestones, updates regarding Haduvio and company performance are expected to shape public interest in Trevi’s operations moving forward.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.